Physician

Raju Kumar Vaddepally, M.D.

According to 2025 Medicare claims, Raju Vaddepally, M.D. (NPI: 1871857391) practices medical oncology in the Naples-Marco Island, FL market, with the plurality of this provider's patient population coming from Collier, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 34105-5020. Vaddepally is affiliated with the BEST CARE COLLABORATIVE, LLC (ACO ID: A4937), participating under the MSSP model.

Vaddepally's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 135 traditional Medicare patients, billed 218 HCPCS/CPT codes, and received $18,937 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 484 prescription claims across 143 beneficiaries totaling $1,651,884 in drug costs, led by Sprycel (Dasatinib). 2023 DME data shows 104 claims. Open Payments data shows 15 records totaling $60,065. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $22,115 to $18,937. In contrast, Part D prescription costs have risen steadily, from $20,671 to $1,651,884. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	131	245	$22,115
2019	304	1,040	$82,639
2020	304	932	$73,123
2021	358	1,135	$114,693
2022	378	1,088	$105,080
2023	349	1,007	$92,959
2024	135	218	$18,937

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	64	242	$20,671
2016	52	180	$61,364
2017	38	122	$77,238
2018	47	147	$120,040
2019	99	444	$1,221,423
2020	131	626	$1,991,086
2021	136	578	$1,420,928
2022	165	709	$1,787,398
2023	174	772	$2,539,905
2024	143	484	$1,651,884

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	11	$2,225
2020	N/R	N/R	N/R
2021	N/R	51	$3,500
2022	N/R	133	$7,655
2023	N/R	104	$9,253
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	29	29	$136
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	45	47	$104
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	13	22	$96
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	43	68	$64

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Sprycel	Dasatinib	19	570	$318,856
Xtandi	Enzalutamide	19	570	$266,295
Abiraterone Acetate	Abiraterone Acetate	29	870	$88,188
Xarelto	Rivaroxaban	16	580	$10,909
Anastrozole	Anastrozole	30	1,710	$457

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$93	ARRAY BIOPHARMA INC
Research Payments	Reported research-related payment or transfer-of-value amount.	12	$59,972	Regeneron Pharmaceuticals, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Raju Kumar Vaddepally, M.D.?

Tedicare shows public-source Medicare data for Raju Kumar Vaddepally, M.D. (NPI 1871857391), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Raju Kumar Vaddepally, M.D. have ACO affiliation data?

Raju Kumar Vaddepally, M.D. is shown with ACO affiliation data for BEST CARE COLLABORATIVE, LLC (MSSP, ACO ID A4937).

What billing organization is linked to Raju Kumar Vaddepally, M.D.?

Raju Kumar Vaddepally, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Raju Kumar Vaddepally, M.D. have Open Payments data?

Raju Kumar Vaddepally, M.D. has 15 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.